Positive Sentiment Still Eludes Nirman Agri Genetics Limited (NSE:NIRMAN) Following 26% Share Price Slump
Jul 19
Have your own idea? Try our Stock Screener
Indian (NIFTY) Biotech Industry Analysis
UpdatedJul 20, 2025
DataAggregated Company Financials
Companies9
- 7D6.3%
- 3M17.2%
- 1Y19.6%
- YTD6.1%
Over the last 7 days, the Biotech industry has risen 6.3%, driven by gains from Biocon of 4.1%. Meanwhile, Nirman Agri Genetics actually underperformed within the industry, shrinking 15% in the last week. This takes the industry's 12 month performance to a gain of 20%. As for the next few years, earnings are expected to grow by 20% per annum.
Industry Valuation and Performance
Has the Indian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 22 Jul 2025 | ₹581.3b | ₹163.7b | ₹10.6b | 56.2x | 54.7x | 3.6x |
| Thu, 19 Jun 2025 | ₹457.9b | ₹163.8b | ₹10.6b | 48.1x | 43.1x | 2.8x |
| Sat, 17 May 2025 | ₹461.0b | ₹163.8b | ₹10.6b | 56.3x | 43.5x | 2.8x |
| Mon, 14 Apr 2025 | ₹427.3b | ₹158.8b | ₹8.5b | 47.1x | 50.1x | 2.7x |
| Wed, 12 Mar 2025 | ₹435.3b | ₹158.9b | ₹8.4b | 48.9x | 52.1x | 2.7x |
| Fri, 07 Feb 2025 | ₹525.3b | ₹158.7b | ₹8.3b | 59.1x | 63.4x | 3.3x |
| Sun, 05 Jan 2025 | ₹498.0b | ₹159.6b | ₹14.5b | 64x | 34.3x | 3.1x |
| Tue, 03 Dec 2024 | ₹508.8b | ₹159.6b | ₹14.5b | 39.1x | 35x | 3.2x |
| Thu, 31 Oct 2024 | ₹432.2b | ₹157.8b | ₹15.7b | 43.3x | 27.5x | 2.7x |
| Sat, 28 Sep 2024 | ₹490.1b | ₹157.7b | ₹15.7b | 33.9x | 31.2x | 3.1x |
| Mon, 26 Aug 2024 | ₹463.2b | ₹157.7b | ₹15.7b | 30.1x | 29.5x | 2.9x |
| Wed, 24 Jul 2024 | ₹441.0b | ₹157.4b | ₹10.4b | 47.7x | 42.6x | 2.8x |
| Fri, 21 Jun 2024 | ₹442.6b | ₹157.4b | ₹10.4b | 45.1x | 42.7x | 2.8x |
| Sun, 19 May 2024 | ₹395.9b | ₹165.6b | ₹10.2b | 46.5x | 38.8x | 2.4x |
| Tue, 16 Apr 2024 | ₹345.9b | ₹155.4b | ₹12.0b | 35.4x | 28.8x | 2.2x |
| Thu, 14 Mar 2024 | ₹327.9b | ₹155.4b | ₹12.0b | 30.9x | 27.3x | 2.1x |
| Sat, 10 Feb 2024 | ₹357.2b | ₹161.0b | ₹12.2b | 53.7x | 29.2x | 2.2x |
| Mon, 08 Jan 2024 | ₹381.3b | ₹145.0b | ₹5.3b | 60.7x | 72.6x | 2.6x |
| Wed, 06 Dec 2023 | ₹320.8b | ₹145.0b | ₹5.3b | 53.9x | 61x | 2.2x |
| Fri, 03 Nov 2023 | ₹294.9b | ₹133.6b | ₹4.7b | 43.3x | 62.4x | 2.2x |
| Sun, 01 Oct 2023 | ₹355.5b | ₹133.8b | ₹4.8b | 30.6x | 74.4x | 2.7x |
| Tue, 29 Aug 2023 | ₹443.7b | ₹142.3b | ₹7.2b | 36.1x | 61.8x | 3.1x |
| Thu, 27 Jul 2023 | ₹325.9b | ₹120.4b | ₹4.5b | 42.4x | 72.3x | 2.7x |
| Sat, 24 Jun 2023 | ₹310.3b | ₹120.4b | ₹4.5b | 40.8x | 68.8x | 2.6x |
| Mon, 22 May 2023 | ₹319.0b | ₹106.8b | ₹16.2b | 27.5x | 19.7x | 3x |
| Wed, 19 Apr 2023 | ₹308.4b | ₹106.6b | ₹16.4b | 14.5x | 18.9x | 2.9x |
| Fri, 17 Mar 2023 | ₹293.7b | ₹106.5b | ₹16.3b | 30.5x | 18x | 2.8x |
| Sun, 12 Feb 2023 | ₹321.0b | ₹99.2b | ₹17.9b | 30.8x | 17.9x | 3.2x |
| Tue, 10 Jan 2023 | ₹341.1b | ₹99.2b | ₹18.0b | 33x | 19x | 3.4x |
| Thu, 08 Dec 2022 | ₹363.7b | ₹99.2b | ₹18.0b | 35.7x | 20.3x | 3.7x |
| Sat, 05 Nov 2022 | ₹362.4b | ₹95.5b | ₹18.2b | 31.5x | 19.9x | 3.8x |
| Mon, 03 Oct 2022 | ₹382.1b | ₹95.5b | ₹18.1b | 32.5x | 21.1x | 4x |
| Wed, 31 Aug 2022 | ₹406.9b | ₹95.5b | ₹18.1b | 34x | 22.4x | 4.3x |
| Fri, 29 Jul 2022 | ₹422.5b | ₹92.1b | ₹17.7b | 31.4x | 23.9x | 4.6x |
Price to Earnings Ratio
23.9x
Current Industry PE
- Investors are optimistic on the Indian Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 54.7x which is higher than its 3-year average PE of 40.6x.
- The 3-year average PS ratio of 2.9x is lower than the industry's current PS ratio of 3.6x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have declined 16% per year over the last three years.
- Meanwhile revenues for these companies have grown 21% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Indian Healthcare industry?
| IN Market | 0.28% | |
| Healthcare | 1.82% | |
| Biotech | 6.31% | |
| Biotech | 6.31% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BIOCON Biocon | ₹394.65 | 4.1% +₹20.8b | 17.7% | PE52x | |
| 524669 Hester Biosciences | ₹1.89k | 1.9% +₹297.7m | -26.9% | PE58.4x | |
| PANACEABIO Panacea Biotec | ₹427.95 | 0.6% +₹165.4m | 213.3% | PS4.7x | |
| 532039 Zenotech Laboratories | ₹61.52 | 0.9% +₹32.3m | -8.1% | PE66.9x | |
| 514336 Genesis IBRC India | ₹25.77 | 10.2% +₹30.9m | 70.7% | PE9.6x |